Lilly's Pipeline Grows, But Wall Street Worried

Mirasol, Feliza
November 2004
Chemical Market Reporter;11/15/2004, Vol. 266 Issue 17, p14
Trade Publication
Focuses on the business performance of pharmaceutical firm, Eli Lilly & Co. as of November 2004. Product offerings; New drug candidates; Concerns over the market performance of the firm's leading brand Zyprexa or olanzapine; Boost in the firm's central nervous system through the acquisition of Merck KgaA's developmental insomnia drug, EMD281014.


Related Articles

  • Eli Lilly: fewer sleepless nights for investors.  // PharmaWatch: Monthly Review;December2004, Vol. 3 Issue 12, p16 

    Reports that Eli Lilly & Co. has received exclusive rights to develop and market Merck KGaA's EMD-281014 insomnia drug. Potential of the company to generate revenues through its insomnia drug; Efficacy of insomnia drug; Confidence of the company that EMD-281014 represents a novel approach to...

  • Eli Lilly issues reminder to GPs over Zyprexa.  // GP: General Practitioner;10/15/2004, p19 

    The article focuses on the usage of intramuscular olanzapine Zyprexa. The circumstances under which Zyprexa should and should not be used have been highlighted in a letter sent to clinicians by manufacturer Eli Lilly & Co. It follows 49 adverse events, including eight fatalities, among patients...

  • Warning added to Zyprexa label regarding hyperglycaemia/diabetes.  // Reactions Weekly;3/27/2004, Issue 994, p2 

    Reports on the warning added by pharmaceutical company Eli Lilly and Co. to the label of its Zyprexa olanzapine drugs, regarding the risk of hyperglycaemia and diabetes mellitus. Complications associated with hyperglycaemia; Steps to be taken by diabetes mellitus patients who start receiving...

  • Teva: lining up Lilly.  // PharmaWatch: CNS;May 2005, Vol. 4 Issue 5, p9 

    Reports on the approval of Teva Pharmaceutical's olanzapine tablets which is subject to the U.S. District Court finding Eli Lilly's Zyprexa patent invalid. U.S. Food and Drug Administration's tentative approval of Teva's Abbreviated New Drug Application for a generic version of Eli Lilly's...

  • LILLY'S TERIPARATIDE GETS POSITIVE OPINION FROM CPMP.  // Worldwide Biotech;Feb2003, Vol. 15 Issue 2, p8 

    Reports on the positive opinion issued by the European Committee for Proprietary Medicinal Products concerning the teriparatide (rDNA origin) injection from Lilly.

  • Eli Lilly and Co.  // Indianapolis Business Journal;3/24/2003, Vol. 24 Issue 2, p35 

    Features Eli Lilly and Co., an Indianapolis, Indiana-based pharmaceutical company. Stock value; Major shareholders; Executive compensation; Corporate directors.

  • Lilly looms larger. Jefferson, Greg // Indianapolis Business Journal;07/19/99, Vol. 20 Issue 18, p1A 

    Reports on Indianapolis, Indiana-based drug firm Eli Lilly's expansion plan in Indiana. Company profile; Effect on the cultural and economic makeup of Indiana; Pledge of investments for construction and renovation projects; Projects; Addition of employees. INSET: In first speech to Indy...

  • Lilly banks on R&D. Jefferson, Greg // Indianapolis Business Journal;07/26/99, Vol. 20 Issue 19, p1 

    Reports on Eli Lilly and Co.'s plan to invest $1 billion into its pharmaceutical operations in Indianapolis, Indiana. Recruitment of researchers, computer specialists and technicians; Construction of new facilities.

  • Lilly.  // Formulary;Oct2000 Resource Guide, Vol. 35 Issue 10, p54 

    Features the Lilly & Co., a pharmaceutical manufacturer. Therapeutic areas targeted by its research and development; Signature product; Pharmaceutical products that have received approval from the United States Food and Drug Administration.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics